アルツハイマー病患者の運動と行動管理:ランダム化制御試験
Linda Teri1, Laura E Gibbons, Susan M McCurry
1Department of Psychosocial and Community Health, University of Washington, Seattle 98195, USA. lteri@u.washington.edu
JAMA
|October 16, 2003
まとめ
介護者訓練と組み合わせた家庭での運動プログラムは,アルツハイマー病患者の身体機能を改善し,うつ病を軽減しました. この介入は,2年間にわたって施設化が減少する傾向を示した.
科学分野:
- ゲロントロジーはゲロントロジーの学科です.
- 神経学 神経学とは
- リハビリテーション医学 リハビリテーション医学
背景:
- アルツハイマー病 (AD) は,脆弱性や行動障害と関連しています.
- 介護者のサポートは,ADの症状の管理と患者の幸福のために非常に重要です.
研究 の 目的:
- AD患者の介護者訓練と組み合わせた家庭での運動プログラムを評価する.
- プログラムが機能的依存症と制度化率に与える影響を評価する.
主な方法:
- 153人のコミュニティに住むAD患者とその介護者を含むランダム化制御試験です.
- 参加者は,アルツハイマー病における障害の軽減プログラム (RDAD) または通常の医療 (RMC) に割り当てられました.
- RDADプログラムには,3ヶ月の家庭での運動と行動管理トレーニングが含まれていました.
主要な成果:
- RDADの参加者は,RMCと比較して,より多く運動し,制限された活動日数が少なくなりました.
- RDADグループでは,身体的な役割機能とうつ病のスコアで有意な改善が観察されました.
- 2年後に,RDAD患者はよりよい身体機能を維持し,施設入院を減らす傾向を示しました.
結論:
- 運動と介護者訓練の組み合わせは,AD患者の身体的健康と気分を向上させます.
- この統合的アプローチは,アルツハイマー病の症状を管理し,患者のアウトカムを改善するための有望な戦略を提供します.
関連する概念動画
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:21Behavior Modification
Behavioral approaches have often been criticized for ignoring mental processes and focusing solely on observable behavior. However, these approaches provide an optimistic perspective for individuals seeking to change their behaviors. Rather than concentrating on intrinsic personality traits, behavioral approaches suggest that even longstanding habits can be modified by changing the reward contingencies that maintain them.
A real-world application of operant conditioning principles is applied...
A real-world application of operant conditioning principles is applied...